Apr 09, 2020
Roche's Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis' Mayzent and Ofatumumab May Threaten the Brand's Long-Term Dominance
Mar 03, 2020
Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease
Aug 13, 2019
Novartis' Gilenya, Sanofi's Aubagio, Biogen's Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement
May 28, 2019
EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
Oct 08, 2018
Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients
Jun 26, 2018
A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech's Ocrevus Prescribing Patterns
Apr 25, 2018
Recent Chart Audit of Multiple Sclerosis Patients Recently Switched to a New Disease-Modifying Therapy Shines Spotlight on Gains by Genentech's Ocrevus in the Secondary Progressive and Primary Progressive Patient Segments
Mar 22, 2018
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
Mar 13, 2018
Genentech's Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play
Aug 10, 2017
Secondary Progressive Multiple Sclerosis (SPMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017